897 related articles for article (PubMed ID: 29090673)
21. Performance of
Bailey J; Piert M
Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
23. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
24. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
25. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
[TBL] [Abstract][Full Text] [Related]
26. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
27. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
[TBL] [Abstract][Full Text] [Related]
29. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
30.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
31.
Deandreis D; Guarneri A; Ceci F; Lillaz B; Bartoncini S; Oderda M; Nicolotti DG; Pilati E; Passera R; Zitella A; Bellò M; Parise R; Carlevato R; Ricardi U; Gontero P
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2804-2815. PubMed ID: 32314028
[TBL] [Abstract][Full Text] [Related]
32. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
33.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
34. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
35.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
36.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance of
Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198
[TBL] [Abstract][Full Text] [Related]
38. Preliminary results of a
Rousseau C; Le Thiec M; Ferrer L; Rusu D; Rauscher A; Maucherat B; Frindel M; Baumgartner P; Fleury V; Denis A; Morel A; Varmenot N; Debeaupuis E; Campion L; Kraeber-Bodéré F
Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657
[TBL] [Abstract][Full Text] [Related]
39. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
